K
36.49
0.98 (2.76%)
| Penutupan Terdahulu | 35.51 |
| Buka | 35.82 |
| Jumlah Dagangan | 274,383 |
| Purata Dagangan (3B) | 551,311 |
| Modal Pasaran | 2,704,188,672 |
| Harga / Pendapatan (P/E TTM) | 729.80 |
| Harga / Jualan (P/S) | 5.27 |
| Harga / Buku (P/B) | 5.61 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 29 Jul 2025 |
| Margin Keuntungan | -3.52% |
| Margin Operasi (TTM) | 9.63% |
| EPS Cair (TTM) | -0.240 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 72.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 2.17% |
| Nisbah Semasa (MRQ) | 3.66 |
| Aliran Tunai Operasi (OCF TTM) | 44.03 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 25.15 M |
| Pulangan Atas Aset (ROA TTM) | -1.77% |
| Pulangan Atas Ekuiti (ROE TTM) | -3.81% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Menaik | Bercampur |
| Drug Manufacturers - Specialty & Generic (Global) | Menaik | Bercampur | |
| Stok | Kiniksa Pharmaceuticals, Ltd. | Menaik | Menaik |
AISkor Stockmoo
1.9
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | 3.5 |
| Osilator Teknikal | 4.0 |
| Purata | 1.90 |
|
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 3.80% |
| % Dimiliki oleh Institusi | 97.31% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 60.00 (TD Cowen, 64.43%) | Beli |
| Median | 54.00 (47.99%) | |
| Rendah | 45.00 (Wells Fargo, 23.32%) | Beli |
| Purata | 53.00 (45.25%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 34.88 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| TD Cowen | 29 Sep 2025 | 60.00 (64.43%) | Beli | 38.77 |
| Wells Fargo | 25 Sep 2025 | 45.00 (23.32%) | Beli | 35.51 |
| 09 Jul 2025 | 42.00 (15.10%) | Beli | 28.80 | |
| Jefferies | 29 Jul 2025 | 54.00 (47.99%) | Beli | 30.37 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| TESSARI EBEN | - | 38.77 | -42,000 | -1,628,340 |
| Jumlah Keseluruhan Kuantiti Bersih | -42,000 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -1,628,340 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 38.77 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| TESSARI EBEN | Pegawai | 29 Sep 2025 | Jual automatik (-) | 42,000 | 38.77 | 1,628,340 |
| TESSARI EBEN | Pegawai | 29 Sep 2025 | Pelaksanaan pilihan | 42,000 | - | - |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 28 Aug 2025 | Pengumuman | Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences |
| 29 Jul 2025 | Pengumuman | Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution |
| 24 Jul 2025 | Pengumuman | Kiniksa Pharmaceuticals to Report Second Quarter 2025 Financial Results on July 29, 2025 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |